To include your compound in the COVID-19 Resource Center, submit it here.

New compound kills tumor cells with spliceosome mutations

In a Nature Medicine study, researchers at H3 Biomedicine Inc. (Cambridge, Mass.) described development and preclinical proof-of-efficacy data for Phase I candidate H3B-8800,

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE